A detailed history of Lmr Partners LLP transactions in Savara Inc stock. As of the latest transaction made, Lmr Partners LLP holds 36,800 shares of SVRA stock, worth $117,760. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,800
Previous 100,000 63.2%
Holding current value
$117,760
Previous $403,000 61.29%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$3.96 - $5.07 $250,272 - $320,424
-63,200 Reduced 63.2%
36,800 $156,000
Q2 2024

Aug 14, 2024

BUY
$3.66 - $5.34 $366,000 - $534,000
100,000 New
100,000 $403,000
Q1 2023

May 15, 2023

BUY
$1.6 - $2.82 $81,227 - $143,162
50,767 New
50,767 $98,000
Q3 2021

Nov 15, 2021

SELL
$1.18 - $1.64 $31,756 - $44,135
-26,912 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$1.51 - $2.29 $40,637 - $61,628
26,912 New
26,912 $46,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $365M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Lmr Partners LLP Portfolio

Follow Lmr Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.